Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Discover key insights from Trevi Therapeutics' Q3 2025 earnings call, including clinical progress, strong financials, and upcoming regulatory milestones.

Trevi Therapeutics recently reported its third quarter earnings, highlighting a net loss of US$11.8 million and progress toward advancing its chronic cough drug Haduvio into Phase 3 clinical trials.

Trevi Therapeutics (NASDAQ: TRVI) will release its quarterly earnings report on Thursday, 2025-11-13. Here's a brief overview ...

Morgan Stanley analyst Judah Frommer raised the firm’s price target on Trevi Therapeutics (TRVI) to $19 from $18 and keeps an Overweight rating on ...

Trevi Therapeutics (TRVI) has caught the attention of investors after recent updates on its chronic cough clinical programs. The company is moving ahead with Phase 3 plans for IPF-related chronic ...

Cantor Fitzgerald analyst Joshua Schimmer reiterated a Buy rating on Trevi Therapeutics today and set a price target of $25.00. Meet Your ETF AI Analyst. Discover how TipRanks' ET ...

"I know that I'm a woman deep down," Trevi Moran said Trevi Moran has come out as a transgender woman. On Sunday, the 21-year-old YouTube star and former X Factor contestant shared the news with her 1 ...